AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer on April 29, 2025 AACR25 Boehringer cellular targeting durability Malignant neoplasm of lung Non-Small Cell Lung Carcinoma Zongertinib +
Cargo Therapeutics Discontinues Lead CAR-T Program Due to Poor Durability and Safety Concerns on January 31, 2025 CAR-T therapy cargo receptor ligand activity Clinical Trials Discontinuation (procedure) durability firi-cel Safety +